Supernus Pharmaceuticals (SUPN) Price Target Raised to $60.00 at Stifel Nicolaus

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price hoisted by Stifel Nicolaus from $50.00 to $60.00 in a research report sent to investors on Friday. They currently have a buy rating on the specialty pharmaceutical company’s stock.

SUPN has been the subject of a number of other reports. ValuEngine upgraded shares of Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, May 12th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a hold rating to a strong sell rating in a report on Saturday, May 5th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a report on Friday, January 26th. Finally, Berenberg Bank initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, February 1st. They issued a buy rating and a $66.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Supernus Pharmaceuticals has an average rating of Buy and an average price target of $52.55.

Supernus Pharmaceuticals traded up $1.60, reaching $57.25, during trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 746,812 shares, compared to its average volume of 903,531. Supernus Pharmaceuticals has a 12-month low of $33.30 and a 12-month high of $59.05. The company has a market cap of $2.88 billion, a price-to-earnings ratio of 45.44 and a beta of 1.14. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.74 and a current ratio of 4.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. The firm had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. sell-side analysts predict that Supernus Pharmaceuticals will post 1.9 EPS for the current year.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 67,132 shares of the business’s stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $53.11, for a total transaction of $3,565,380.52. Following the completion of the sale, the vice president now directly owns 32,500 shares in the company, valued at $1,726,075. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Victor Vaughn sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $45.33, for a total transaction of $2,719,800.00. Following the sale, the vice president now owns 24,344 shares of the company’s stock, valued at $1,103,513.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,850 shares of company stock valued at $7,596,524. 6.20% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. Summit Trail Advisors LLC lifted its position in shares of Supernus Pharmaceuticals by 4,144.2% during the first quarter. Summit Trail Advisors LLC now owns 1,617,365 shares of the specialty pharmaceutical company’s stock worth $1,617,000 after purchasing an additional 1,579,257 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Supernus Pharmaceuticals by 166.0% during the first quarter. JPMorgan Chase & Co. now owns 461,586 shares of the specialty pharmaceutical company’s stock worth $21,140,000 after purchasing an additional 288,059 shares in the last quarter. Stephens Investment Management Group LLC acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth $7,316,000. BlackRock Inc. lifted its position in shares of Supernus Pharmaceuticals by 2.5% during the first quarter. BlackRock Inc. now owns 7,071,947 shares of the specialty pharmaceutical company’s stock worth $323,898,000 after purchasing an additional 169,717 shares in the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth $7,761,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply